Immunotherapy in Metastatic Genito-Urinary Malignancies: A Prelude to Cure?
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (27 February 2022) | Viewed by 6038
Special Issue Editor
Special Issue Information
Dear Colleagues,
Urogenital cancers originate from the kidney, urothelium (renal pelvis, ureter, urinary bladder, urethra), prostate, testes and penis. This Special Issue will focus on kidney cancer (renal-cell carcinoma, RCC) and urothelial cancer (UC). Although the majority of patients with non-metastatic disease recover, most patients with metastatic RCC (mRCC) and UC (mUC) die from their disease. Immunotherapy has long been used with success in both tumors. For the last 50 years we have known that interleukin could cure about 10% of mRCC, while the intravesical administration of Bacillus–Calmette Guerin (BCG) still remains the treatment of choice for high-risk, non-muscle-invasive bladder cancer. Recent advents in our understanding of how cancer evades immune surveillance have influenced the modern era of cancer immunotherapy. A major mechanism of immune escape operates through the interaction between the T cell receptor programmed-death 1 (PD-1) and its ligand (PD-L1), which is produced by the tumor. The development of anti-PD1 and anti-PDL1 agents, which disrupt this interaction and restore anti-cancer immune response, represents the most recent milestone in anti-cancer therapy. Such agents are now being used in almost all human malignancies. mRCC and mUC have been shown to cause prolongation of survival. Moreover, responses to these agents are long-lived in about 20% of treated patients. This Special Issue of Life aims to provide a critical review of the state-of-the-art in immunotherapy of mRCC and mUC, and especially the significance of long-term disease remission in our effort to cure a substantial proportion of patients with these cancers.
Dr. Aristotelis Bamias
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cancer
- urothelial cancer
- immunotheraphy
- long-term survival
- biomarkers
